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Policy Points:
 The policy context of direct-to-consumer personal genomic testing
(DTC-PGT) has been evolving over the last decade, with little em-
pirical data available about consumers’ perspectives.
 A majority of consumers of DTC-PGT supported expanded access to
services and their integration into the medical context and opposed
more governmental regulation.
 Consumers’ attitudes about access to services and regulation did not
vary based on the specific genetic risk information they received from
companies, but may vary based on whether consumers perceived their
DTC experience negatively.
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Context: While policymakers have been considering the appropriateness of
direct-to-consumer personal genomic testing (DTC-PGT) for more than a
decade, there is little empirical data on consumers’ views regarding the regu-
lation of these products. No research has assessed whether consumers’ personal
experience with testing is related to their views about access to and regulation
of DTC tests.
Methods:Data were analyzed from the PGen Study, a longitudinal prospective
cohort of DTC-PGT customers of 23andMe (n = 564) and Pathway Genomics
(n = 377; total N = 941). Consumers were sent an electronic survey before
receiving genetic test results and again 6 months after receipt of results.
Findings: At the 6-month follow-up, more than 80% of participants believed
that people have a right to access genetic information directly, that parents
should be able to get DTC-PGT testing for their children, and that genetic
information should be kept private. Participants supported health insurance
coverage of PGT (60%), wider availability of PGT (68%), and inclusion of
genetic information in medical records (63%). Participants were less support-
ive of government regulation (28%) and restricting testing to clinical settings
(14%). Conservative political ideology was associated with less support for
government regulation (P < 0.001), as was feeling more confident in one’s
genetic knowledge (P < 0.05). Participants’ level of computed genetic risk for
common diseases, as indicated by their actual test results received from compa-
nies, showed no relationship with attitudes. However, those who perceived that
they had received elevated risk results expressed lower support for expanded
availability and incorporation of PGT into health care (P < 0.01). Those who
reported being upset by their genetic test results were less likely to endorse
access to DTC products without a medical professional (P < 0.01).
Conclusions: PGT consumers supported expanded access to these services and
opposed additional regulation. Users who had a negative personal experience
with PGT testing were less supportive of expanded availability without a
medical professional.
Keywords: genetic testing, ethics, regulation, public opinion.
W hether and how to regulate access to direct-to-consumer personal genomic testing (DTC-PGT)—commercial services that provide genetic risk information
directly to consumers outside of the traditional clinical context—have
been topics of scrutiny for more than 10 years.1-3 Scholars have examined
the potential benefits of and limitations to making genetic test results
directly available to consumers, arguing, for instance, that the potential
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impact of genetic risk information on consumers’ privacy, health, health
care utilization, behavior changes, and well-being warrant heightened
attention and regulation.1-7 While early discussions about the potential
consequences of PGT were largely speculative, recent studies of actual
PGT consumers that examine the psychosocial risks of testing and its
impact on the health care system provide important information for
policymakers.8 Data on users’ attitudes and perspectives on access to
PGT testing are also important since experience in other policy con-
texts shows that political pressures can shape the regulatory process.9
Moreover, informed interest groups with strong opinions about the de-
sirability of government oversight (such as PGT consumers) may be
invested in shaping regulatory processes, such as through public com-
ment periods and other mechanisms.10
In this study, we examined longitudinal data on consumers’ experi-
ences with PGT and the impact of those experiences on their views about
the availability of PGT and of its regulation. We examined consumers’
actual genetic test results—and their experience with testing—as pre-
dictors of their subsequent attitudes about PGT services, which previous
research has not done.
Background
Regulation of Consumer Access to Genetic
Services
Prior to 2007, US federal oversight of PGT was extremely limited.1
Initial federal government scrutiny (such as the Secretary’s Advisory
Committee on Genetics, Health, and Society convened by the Depart-
ment of Health and Human Services and the Government Account-
ability Office) focused on examining reliability, accuracy, and clinical
utility concerns of these new services.11-13 However, it took a proposed
rapid increase in consumer access to DTC genetic testing—specifically,
Pathway Genomics’ 2010 proposal to begin selling its product at Wal-
greens across the country—to spur action by the US Food and Drug
Administration (FDA).14 The FDA’s first round of cautionary letters to
almost all DTC-PGT providers served to push most out of the DTC
market or out of business entirely.15 23andMe Inc alone began filing for
premarket authorization of its Personal Genome Service in July 2013,
while continuing to sell its product.16 When 23andMe launched a new
294 S.E. Gollust et al.
national advertising campaign later that year, the FDA once again took
note of the abrupt potential shift in access and sent 23andMe a more
dire warning letter ordering that it stop marketing its health-related
tests immediately.17 In response, 23andMe reduced its online offering
initially to ancestry testing only, but recently re-entered the market
with 36 carrier screens in addition to nonmedical “wellness,” “trait,”
and ancestry testing.18 In April 2017, the company obtained FDA ap-
proval to market 10 genetic health risk tests for conditions including
Alzheimer’s disease, Parkinson’s disease, and hereditary hemochromato-
sis. While regulatory oversight of DTC-PGT services has been evolving
over the past 10 years, there has been very little research examining
how consumers themselves think about restricting or expanding access
to these services.
Public and Consumer Attitudes About Personal
Genomic Testing
Given that the general public to date has relatively low exposure to PGT,
most existing survey research of the general public has examined trends
in awareness,19-22 not more detailed assessment of what the public
thinks should be done about it. In an exception, Almeling and Gadarian
surveyed a national sample of Americans in 2011 and asked a single
question regarding public attitudes about DTC genetic testing; they
found that 65% of respondents agreed that clinicians should be involved
in all genetic testing.23 A survey of social network users similarly found
that most (67%) agreed that PGT companies should provide a medical
expert to interpret results, and half (51%) supported federal regulation
of PGT companies.24 Members of the general public, however, are likely
to consider access to PGT quite differently from informed consumers of
these services. While other studies of early users of PGT have examined
consumers’ beliefs about testing and their motivations to pursue it,25-28
only one has examined consumers’ perceptions of policy oversight in
particular. Bollinger, Green, and Kaufman surveyed consumers of Nav-
igenics, 23andMe, and deCODEme (N = 1,046) about their attitudes
toward PGT services and their preferences related to regulation.29 They
found that most PGT consumers (66%) agreed that it was important
that DTC tests be available without government oversight.29
Social science research illuminates the factors that generally ex-
plain variation in the public’s perceptions of policy matters. This
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body of research demonstrates that individual demographic character-
istics (such as gender or socioeconomic status), attitudes about groups
in society, and political characteristics shape individuals’ perspectives
about social policy issues.30 Within the health context in particular,
researchers have described the factors that predict Americans’ opin-
ions of issues on a range of health policy topics, from health dispar-
ities to obesity prevention, with political liberals generally support-
ing more governmental action compared to political conservatives, and
racial and ethnic minorities more supportive of government action than
whites.31,32
Less clear is the relationship between individuals’ “self-interest” in
an issue and their attitudes about policy action related to that issue.33
Studies find, for instance, that people’s presumed “interest” in a pol-
icy arena (such as low-income individuals’ interest in welfare reform,
or smokers’ interest in tobacco regulation) is a less important factor
shaping support for policies than one might expect.34 In fact, the as-
sociation of self-interest with policy opinion is variable and depends
on the context, particularly how salient the risks and benefits of a par-
ticular policy are to that individual.35 Attitudes about PGT offer an
illuminating context in which to explore these relationships between
self-interest, salience of risk, and opinion about policy. All consumers
who have themselves sought access to DTC-PGT are likely supportive
of that access and have an interest in ensuring access to these services,
as the Bollinger and colleagues study revealed.29 But a more nuanced
investigation of consumers’ “interest” in regulating access should also
consider consumers’ personal and varying experience with PGT. On the
one hand, receipt of results suggesting elevated risk for a disease could
lead consumers to be less supportive of expanded access to genetic ser-
vices and more supportive of regulatory oversight. This might be the
case if these consumers perceive that the elevated risk results could lead
to negative psychosocial consequences and/or they could come to believe
that having clinician involvement is important to navigate the impli-
cations of the test results. On the other hand, receiving elevated risk
results could lead consumers to be more supportive of expanded access
and less supportive of regulatory oversight, if, for example, they per-
ceive the results as having important personal value or medical utility
or if they value the experience of receiving such results without the dis-
criminatory risk of having such information included in their medical
record.
296 S.E. Gollust et al.
Research Objectives
In this study, we leveraged data from a sample of 941 participants in
a longitudinal study of consumers of 2 PGT companies (23andMe and
Pathway) with the goal of examining the contribution of an “objective”
measure of genetic risk (ie, level of disease risk as predicted by PGT) as
well as consumers’ “subjective” responses to that genetic testing (eg, their
perceptions of their results andwhether they felt upset) and to consumers’
attitudes about access to personal genomic services. Specifically, our
research objectives are twofold: (1) to describe consumers’ attitudes
toward access to and regulation of PGT, and (2) to determine whether
information about genetic risk and test experience (risk calculated by
companies and consumers’ perceptions of their own genetic risk results)
contribute to these attitudes about access to and regulation of PGT, after
accounting for individuals’ demographic and political characteristics.
The paper concludes with a discussion of the role of consumer attitudes
about regulation in light of the dynamic policy context around PGT
services.
Methods
Data
Data for this study come from the Impact of Personal Genomics
(PGen) Study, a collaboration between researchers at Brigham &
Women’s Hospital/HarvardMedical School and the University ofMichi-
gan School of Public Health; scientists at 23andMe (Mountain View,
California; www.23andme.com) and Pathway (San Diego, California;
www.pathway.com), and survey research experts at a private, third-
party research firm, SoundRocket (previously Survey Sciences Group;
Ann Arbor, Michigan). The Partners Human Research Committee and
the University of Michigan Health Sciences and Behavioral Sciences
Institutional Review Board approved the study. Complete details of
the academic-industry partnership and study design, including par-
ticipant recruitment, survey design, and response rates, are detailed
elsewhere.36,37
Consumers were recruited between March and July 2012 (prior to the
FDA action against 23andMe described in the introduction) through
invitation emails sent to 3,900 23andMe customers who purchased
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DTC-PGT during this period and participated in the company’s in-
formed consent process for general research studies. In contrast, Pathway
customers were recruited during this same time period through 2 ap-
proaches: through banner advertisements on the company’s website and
through an email invitation to members of the health-based social net-
working site PatientsLikeMe (www.patientslikeme.com). Participants
recruited by way of this latter path were invited to order DTC-PGT at a
subsidized rate through Pathway. After ordering PGT, all study invitees
received a link to the dedicated survey maintained by SoundRocket.
Participants completed an online consent process, and after agreeing to
have their de-identified genetic data and survey responses shared with
academic investigators, they were invited to complete a baseline (pre-
results) survey online. Participants who completed the baseline survey
prior to receiving their DTC-PGT results, and who subsequently re-
ceived and opened their results reports, were eligible for invitation to
the follow-up surveys. Invitations to the follow-up survey reported here
were emailed at 6 months after PGT results were viewed. Both PGT
companies provided regular updates to the survey firm regarding receipt
and viewing of results for the purposes of timing follow-up survey in-
vitations. As noted elsewhere, a total of 1,085 23andMe customers (of
3,900 invited, or 28%) completed the baseline survey; because of the
opt-in recruitment, there is no comparable data to assess the response
from Pathway.38
Measures
Outcome variables: attitudes about access to and regulation of PGT. Our
main dependent variables were 8 survey items that were included in the
6-month survey and measured on a 5-point Likert scale (strongly dis-
agree to strongly agree). The items included the following statements:
“It is important to me that my genetic information is kept private”; “I
think that health insurance should cover personal genomic testing”; “I
think genetic information should be part of a standard medical record”;
“Genetic tests should be available more widely (eg, test kits at drug-
stores)”; “I think the government should put more effort into regulating
personal genomic testing”; “Tests like these should only be available to
people through their doctor”; “I think people have a right to access their
own genetic information without going through amedical professional”;
and “I think that parents should be able to get results for their children if
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they want to.” These items were designed specifically for this study but
were adapted from previous Likert-scale questions used in other research
on consumers of genetic testing.26,27
Independent variables. We examined 2 sets of independent variables
measuring genetic risk information. The first set of independent vari-
ables summarized our measures of company-calculated genetic risk in-
formation. Each company provided individuals’ genetic test results for
ancestry, nonmedical traits, carrier testing, disease risk, and pharma-
cogenomics. For this paper, we focused on the disease risk and pharma-
cogenetic risk results because they were more likely to prompt changes
to health-related policy attitudes (eg, regarding health insurance cov-
erage) than nonmedical traits or ancestry information. Following other
work using the PGen data, we created 2 measures: (1) proportion of
total disease-related test results indicating an elevated risk for the in-
dividual and (2) proportion of total pharmacogenomics-related test re-
sults indicating atypical drug response.38 This proportion score is used
since the 2 companies differed in the total number of results they of-
fered consumers: 23andMe participants received disease-risk estimates
for 29 conditions, while Pathway participants received estimates for 25
conditions; male customers across both companies received 8 pharma-
cogenomic results and female customers received 9 (see van der Wouden
et al.39 for more details). The threshold for elevated versus non-elevated
genetic risk was set at a relative risk (RR) 1.2.40 In sensitivity analyses
examining whether the specific type of disease risk result matters (for
conditions held in common across the 2 companies), we also constructed
dichotomous measures of cancer-related elevated risk (eg, prostate,
melanoma, lung, colorectal, breast), neurological elevated risk result (eg,
Parkinson’s disease, Alzheimer’s disease, multiple sclerosis), and car-
diovascular elevated risk results (eg, coronary heart disease, atrial
fibrillation).
The second set of independent variables measured perceptions of ge-
netic risk information. We used 2 survey items measured at 6 months:
whether the respondent perceived that they received high-risk results
(all or many vs few or none) and whether the respondent reported feeling
upset about the results (yes vs no).
To examine whether genetic risk results were independently associ-
ated with attitudes about PGT access and regulation after accounting
for demographic characteristics, we included in our models a set of vari-
ables measured at baseline: age (in years), gender (female vs male), race
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(white vs nonwhite), education (greater than college degree vs college
degree or less), income categories (<$40,000/year; $40,000 to $69,999;
$70,000 to $99,999; $100,000 to 199,999; and $200,000+), and health
insurance status (insured vs uninsured). We included a measure of polit-
ical ideology, based on political science literature examining the robust
association of political predispositions on policy-relevant attitudes,33
measured as liberal, moderate, or conservative. We also included a mea-
sure of baseline self-rated health (1 item from the SF-36 questionnaire41)
to adjust for possible confounding of the genetic risk results with the
respondents’ overall health. This was measured on a 5-point ordinal
scale: “Would you say that in general your health is excellent, very good,
good, fair, or poor?” (coded 1 to 5).
We also included 2 attributes of individuals that are specific to the
context of genetics: self-assessed genetic knowledge and perceived self-
efficacy with genetic information. Genetic knowledge was measured
using 9 true/false statements designed to reflect understanding of facts
about genetics and genetic testing. Self-efficacy, or confidence in one’s
ability to use genetic information, was measured as 5 items to which
participants agreed or disagreed, such as “I am confident in my ability
to understand information about genetics.” Details on these items and
scoring are reported elsewhere.42 Finally, given the different recruitment
approaches and sample composition coming from the 2 DTC companies,
we included an indicator variable for whether the participant was a
Pathway consumer as compared to a 23andMe consumer.
Analysis
Study participants who completed both the baseline and 6-month sur-
veys, and who had no missing data on the 8 outcome variables, the
genetic risk results, and the covariates described above, were eligible for
inclusion in the current analysis. The first step in the analysis was to esti-
mate the frequencies of the 8 main attitude and opinion measures. Next,
to reduce the number of outcomes examined, we conducted a principal
component analysis on the 8 items (which revealed 4 distinct factors,
described in Results, below) with varimax rotation. We conducted mul-
tivariable linear regression on the 4 outcomes, regressing the measures
on demographics, political ideology, self-rated health, genetic knowl-
edge, self-efficacy, calculated genetic risk information results, and per-
ceived response to genetic risk. In initial specifications, we included the
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calculated genetic risk and perceived response to genetic risk in separate
models (out of concern of collinearity), but because all model variance
inflation factors were under 3, we report the model with all covariates in-
cluded simultaneously. Models estimated with ordered logit regression
for the 2 nonscalarmeasures were substantively identical. Finally, we per-
formed a series of sensitivity analyses measuring the genetic risk results
as disease-specific risk results (eg, any cancer result, any cardiovascular
result, any Alzheimer’s high-risk result, as described above). All analyses
were performed using SAS 9.3 (SAS Institute, Cary, North Carolina).
Results
Of the 1,042 study participants who completed both baseline and
6-month surveys, 941 had non-missing data on all key outcomes and co-
variates and were included in the current analysis. Of these, 377 (40.1%)
were Pathway customers, while 564 (59.9%) were 23andMe customers.
Characteristics of the analytic sample are displayed in Table 1, for the
full sample and separately by each company. Consistent with previous
reports on this survey population,36 the sample was majority white and
highly educated, with about half havingmore than a college degree;more
than 60% had a household income of more than $70,000 a year. They
were politically liberal and described their health as good, very good, or
excellent. Pathway customers tended to have somewhat lower education
and income and were in slightly poorer health than 23andMe customers.
Figure 1 displays participants’ attitudes about PGT access and regu-
lation. These results depict a sample of individuals who were generally
very supportive of the practice of consumer access to genetic test results
and wary of additional regulatory attention. Most participants agreed
that people should have a right to access their genetic information with-
out going through a doctor (89.9%) and that parents should be able
to get results for their children (81.5%). Participants also wanted to
maintain control of their information, with 83.2% agreeing overall and
60.4% strongly agreeing that it is important that genetic information
is kept private. Participants’ views were less uniform about the routine
incorporation of genetic information into health care, but a strong ma-
jority of participants agreed that health insurance should cover personal
genomic testing (60.3% agreed overall) and that genetic information
should be a standard part of the medical record (62.9% agreed overall).
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Table 1. Descriptive Characteristics of Study Sample of Consumers of
Direct-to-Consumer Genetic Testing (N = 941)
Characteristic
23andMe
(n = 564)
Pathway
(n = 377)
Total
(N = 941)
Age, years
Mean ± SD 49.2 ± 16.2 42.5 ± 13.8 46.5 ± 15.6
Range 21-94 19-79 19-94
Gender
Female 305 (54.1%) 257 (68.2%) 562 (59.7%)
Race/ethnicity
White 485 (86.0%) 320 (84.9%) 805 (85.5%)
Nonwhite 79 (14.0%) 57 (15.1%) 136 (14.5%)
Hispanic or Latino 30 (5.3%) 18 (4.8%) 48 (5.1%)
Education
College or less 263 (46.6%) 221 (58.6%) 484 (51.4%)
More than college 301 (53.4%) 156 (41.4%) 457 (48.6%)
Household income, USD
<$40,000 69 (12.2%) 97 (25.7%) 166 (17.6%)
$40,000-$69,999 107 (19.0%) 67 (17.8%) 174 (18.5%)
$70,000-$99,000 117 (20.7%) 80 (21.2%) 197 (20.9%)
$100,000-$199,999 173 (30.7%) 111 (29.4%) 284 (30.2%)
$200,000+ 98 (17.4%) 22 (5.8%) 120 (12.8%)
Health insurance
Uninsured 22 (3.9%) 20 (5.3%) 42 (4.5%)
Political ideology
Liberal 372 (66.0%) 220 (58.4%) 592 (62.9%)
Moderate 92 (16.3%) 86 (22.8%) 178 (18.9%)
Conservative 100 (17.7%) 71 (18.8%) 171 (18.3%)
Self-rated health
Excellent 106 (18.8%) 35 (9.3%) 141 (15.0%)
Very good 253 (44.9%) 128 (34.0%) 381 (40.5%)
Good 158 (28.0%) 119 (31.6%) 277 (29.4%)
Fair 40 (7.1%) 64 (17.0%) 104 (11.1%)
Poor 7 (1.2%) 31 (8.2%) 38 (4.0%)
Self-assessed genetic literacy
Mean ± SD 8.2 ± 0.9 8.1 ± 1.0 8.2 ± 0.9
Range 4-9 4-9 4-9
Genetic self-efficacy
Mean ± SD 29.1 ± 5.5 29.2 ± 5.6 29.1 ± 5.6
Range 5-35 5-35 5-35
Abbreviations: SD, standard deviation.
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% Agreeing with Each Statement
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More than two-thirds (68.3%) agreed that genetic tests should be avail-
able even more widely, such as in drug stores. Correspondingly, only
14.3% agreed that tests like these should only be available to people
through their doctor. Despite these views supporting greater access to
PGT, a small but sizable proportion (27.8%) agreed that the govern-
ment should put more effort into regulating PGT. See the Appendix for
the distribution of participants’ perceptions on these 8 items across all
5 response categories.
Principal component factor analysis revealed 4 factors derived from
these 8 items, which accounted for 69.5% of the overall variance. The
first, which we refer to as “expanded PGT availability and inclusion
in health care,” consisted of the average of 4 items: health insurance
coverage of tests, genetic results as part of the medical record, tests
available more widely, and parents getting test results for children. The
second factor, which we call “access without a medical professional,”
consists of the difference of 2 items: that people have the right to
access the information without a medical professional and that these
tests should only be available through the doctor. The last 2 items
did not factor with either of these outcomes and we retained them as
individual items: that government should regulate these services and
the importance of keeping genetic information private.
Table 2 displays the associations of individual-level characteristics
with these 4 attitudinal outcomes. Few individual characteristics were
significantly associated with attitudes. Women and people earning in-
comes between $100,000 and $200,000 were less enthusiastic about ex-
panded PGT availability than men and those earning less than $40,000
a year. Liberals were more likely than political moderates, and conserva-
tives less likely than political moderates, to support additional govern-
ment regulation of these services; no other demographic characteristics
were associated with support for regulation. The only characteristic that
was associated with the importance of privacy (which as Figure 1 shows
was important to nearly everyone) was education level, such that people
with more than a college education were more supportive of the impor-
tance of protecting privacy than those with less education. These models
reveal no statistically significant differences in attitudes by other individ-
ual demographic characteristics, such as race, income, or genetic literacy.
Two other variables related to the genetic-testing experience were
associated with attitudes about access to and regulation of PGT. Peo-
ple with higher levels of perceived self-efficacy with genetic information
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Table 2. Factors Associated With Attitudes About Access to and Regu-
lation of Personal Genomic Testing
Demographic
Characteristics
Expanded
Availabilitye
Access
Without
Medical
Professionalf
Government
Should
Regulate
Importance of
Privacy
Age −0.03 (0.02) 0.01 (0.04) −0.05 (0.03) −0.03 (0.02)
Female −0.17 (0.05)c −0.22 (0.12) −0.01 (0.09) 0.08 (0.07)
White (vs nonwhite) −0.04 (0.07) 0.24 (0.16) −0.09 (0.12) 0.00 (0.10)
More than college
education (vs less
than college)
−0.05 (0.05) 0.09 (0.11) 0.05 (0.09) 0.15 (0.07)a
$40k-$69k (vs <$40k) −0.08 (0.08) −0.04 (0.19) −0.03 (0.15) −0.22 (0.12)
$70k-$99k (vs
 $40k)
−0.14 (0.08) 0.07 (0.19) 0.11 (0.14) 0.04 (0.11)
$100k-$200k (vs
 $40k)
−0.14 (0.08) 0.07 (0.18) −0.04 (0.21) 0.04 (0.11)
$200k+ (vs  $40k) −0.02 (0.10) 0.01 (0.22) 0.00 (0.17) −0.06 (0.13)
Insured 0.17 (0.12) −0.20 (0.28) −0.04 (0.21) 0.11 (0.17)
Liberal (compared to
moderate)
0.01 (0.06) 0.11 (0.15) 0.26 (0.11)a −0.01 (0.09)
Conservative
(compared to
moderate)
−0.15 (0.08) −0.05 (0.18) −0.49 (0.14)c 0.14 (0.11)
Self-rated healthd −0.01 (0.03) 0.01 (0.06) 0.02 (0.04) −0.01 (0.04)
Genetic literacy −0.04 (0.03) 0.07 (0.06) −0.03 (0.05) 0.02 (0.04)
Genetic self-efficacy 0.01 (0.02) 0.11 (0.05)a −0.09 (0.04)a 0.02 (0.03)
Genetic risk results
Disease risk score −0.03 (0.02) 0.05 (0.04) −0.01 (0.03) −0.02 (0.02)
Pharmacogenomic risk
score
0.01 (0.01) 0.00 (0.02) −0.01 (0.02) 0.02 (0.01)
Perceived response
Any high-risk results −0.24 (0.07)c 0.04 (0.16) −0.22 (0.12) −0.10 (0.10)
Feeling upset 0.00 (0.06) −0.38 (0.12)b 0.05 (0.09) −0.01 (0.08)
Pathway consumer
(vs 23andMe)
0.28 (0.06)c −0.50 (0.13)c 0.36 (0.10)c −0.08 (0.08)
R-squared 0.083 0.061 0.0786 0.0247
Entries are regression coefficients from linear regression; standard errors (SE) are in paren-
theses.
aP  0.05
bP  0.01
cP  0.001
dSelf-rated health is a measure ranging from 1 to 5, where 5 is poor health.
eThis is a combination of 4 items: parents should be able to get results for children; tests
should be available more widely; insurance coverage; inclusion of genetic information in
the medical record.
fThis is a combination of 2 items: tests like these should only be available through a
doctor and people have a right to access their genetic information without going through
a medical professional.
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(that is, greater confidence in their ability to use and apply genetic infor-
mation) were less likely to support regulation and more likely to support
accessing genetic testing without a medical professional. Reflecting the
very different samples recruited into the study, the test company itself
also proved significant: Customers of Pathway were more likely to sup-
port expanded availability of, and routine medical incorporation of, PGT
(eg, insurance coverage, allowing testing of children, including genetic
information in themedical record), less likely to agree that people should
access genetic testing without a medical professional, and more likely to
support greater regulation than were customers of 23andMe.
Table 2 also reveals that none of the calculated genetic risk results
variables were significantly associated with attitudes about expanded
availability, access without a medical professional, government regu-
lation, or privacy. In follow-up sensitivity analyses (available upon re-
quest from authors), we identified no statistically significant associations
between measures of elevated risk for cancers, neurological conditions,
cardiovascular disease, or Alzheimer’s disease and PGT attitudes. Finally,
these results offer some evidence of an association between perceptions of
genetic risk results and attitudes. Specifically, respondents who reported
that they had received many risk results indicating that they were at
a higher than average risk for disease (compared to none or few such
results) were less likely to agree with expanded availability of and incor-
poration of these services in medical care (eg, health insurance coverage,
inclusion in a medical record, access for children). Respondents who
reported feeling upset about their genetic risk results were less likely
to support access to tests without a medical professional. Figure 2 illu-
minates the major participant factors that were associated with 3 of the
4 outcomes displayed in Table 2: test company (23andMe vs Pathway)
and the 2 measures of perceptions of genetic risk—number of high-risk
results and feeling upset.
Discussion
These survey findings describe PGT consumers as enthusiastic about
expanded access to genetic testing and negative about the prospects
of heightened government regulation. Nearly all participants (89.9%)
believed that people should have access to DTC genetic testing, but
only 27.8% thought that the government should put more effort into
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Figure 2. Factors AssociatedWith Consumers’ Attitudes About Avail-
ability (Panel A), Access (Panel B), and Regulation (Panel C) of Personal
Genomic Testing
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Figures plot the predicted mean values (all measured from 0 to 5) for the
first 3 outcomes reported in Table 2. *P  0.05; **P  0.01; ***P 
0.001 indicates significant difference for the indicated group relative to
the paired group (eg, Pathway vs 23andMe; upset vs not upset; and few
high risks vs many high risks).
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regulation. In fact, a large majority (68.3%) thought that the test kits
should be available more widely through outlets such as drug stores—
the very proposal that focused the FDA on the DTC-PGT industry in
the first place. A large majority of participants (83.2%) believed in the
importance of keeping genetic information private.
Study participants were considerably more enthusiastic about PGT
compared to national population studies or to studies within specific
patient populations. For instance, 2 national studies of Australians43 and
Americans23 both reported majority discomfort with DTC delivery of
genetic test results. In particular, the Australian study found heightened
concerns about privacy, test accuracy, and general comfort levels for
genetic test results delivered DTC compared to through the health care
system.43 AUS national study from 2011 found that 65% of respondents
agreed that “medical professionals should be involved in explaining
test results.”23 Reinforcing that generally healthy consumers are quite
different from patients affected by genetic conditions, it is also notable
that existing studies that focused on patient samples also found lower
levels of support for these types of DTC genetics services. For instance,
a study of cystic fibrosis patients and parents in Belgium demonstrated
considerable skepticism toward commercial companies, with 41% of
participants believing that the law should forbid genetic testing being
offered directly to consumers.44 Similarly, among 86 women at high risk
for breast and ovarian cancer in the United States (Connecticut), only
20% reported support for accessing genetic testing for breast cancer
through online services.45
Considered collectively, these findings—support for more restricted
access to PGT among the general public and specific populations of pa-
tients, and enthusiasm about DTC-PGT access among generally healthy
consumers of these services—suggest that individuals’ level of self-
interest is an important factor shaping attitudes. Aiming to unpack
this “interest” with more nuance, our study design allowed us to ex-
amine how variation in the salience of genetic risk information shapes
attitudes by examining whether people receiving higher-risk genetic
results had different attitudes than those receiving lower-risk genetic
results, holding all other characteristics constant. We did not find that
the genetic risk results calculated by companies that consumers actually
received were associated with their attitudes. (Note that we did not ex-
amine whether respondents’ own prior risk perceptions or family history
moderated the impact of genetic test results on their attitudes, although
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other research does find that personal risk perceptions are important
contributors to consumers’ interest in testing.46,47)
In contrast, consumers’ personal perceptions of the testing experience
did relate to their attitudes about test access and availability: Consumers
who perceived that they received heightened genetic risk results from
their DTC testing (compared to those who reported receiving mainly
lower-risk results) were less enthusiastic about expanded availability
and routine incorporation of PGT into health insurance and the medical
record. In addition, those who experienced negative emotional impact
(feeling upset), compared to those who did not report such emotion,
were less supportive about accessing these services without a medical
professional. However, these perceptions of the testing experience were
not associated with beliefs that the government should put more effort
into regulating tests. Interestingly, participants who, at baseline, felt
more confident in their ability to use and apply genetic information
were both less likely to support regulation and more likely to support
accessing genetic testing without a medical professional—regardless of
what type of genetic risk results they ultimately received.
Attitudes about testingmay vary both by the population (as described
vis-a`-vis disease groups above), as well as the type of genetic testing un-
der consideration. Highly actionable tests or those with highly penetrant
mutations may evoke different attitudes (and from a policy perspective,
may require a different regulatory frameworks [see, eg, the FDA’s dis-
cussion of the varieties of laboratory developed tests48]) than tests with
more moderate risk and without clear clinical utility. However, we did
not observe this in our data. People who received elevated risk results
for Alzheimer’s disease, for which the apolipoprotein E-4 variant con-
fers a relatively high risk of disease (20%-35%), compared to other
conditions covered by DTC-PGT, were no more or less supportive of ex-
panded access than those not receiving such a risk, but we were limited
in the sample size of people who had received such results. More work is
needed to ascertain the relationship between the type of genetic testing
and regulatory approaches; since genetic information provided through
PGT is extremely heterogeneous, a one-size-fits-all approach when it
comes to regulation does not make sense.
Overall, few demographic traits were significantly associated with
attitudes about access to and availability of testing. About a quarter
of the sample supported increased regulation, and political ideology
(identifying as liberal) was, as expected, strongly associated with this
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view. Women were less supportive of expanded availability of PGT and
of access without medical professionals; a previous study by Bloss and
colleagues also indicated that women had more concerns about DTC
testing,27 suggesting heightened caution about these services among
female consumers compared to males. Interestingly, our findings also
revealed important differences by type of consumer. Pathway, which
offered disease risk and pharmacogenomics testing only, and which re-
cruited from a social networking site for personswithmedical conditions,
attracted more medically oriented consumers than 23andMe, which also
offered testing for more nonmedical traits and information. This dif-
ference likely explains why Pathway consumers were more supportive
of the incorporation of tests into medical care, less supportive of access
without medical professionals, and more supportive of regulation.
Limitations
Although the PGen Study has notable strengths (particularly, recruit-
ment of actual customers, integration of genetic risk results, and a
longitudinal design), these results should be considered in light of some
limitations. First, as noted elsewhere, the PGen sample is subject to vol-
unteer bias since participants have to both select PGT and also volunteer
to be part of the study.36 Given that most of these individuals purchased
a PGT product, it is not surprising that they would be supportive of
direct access. However, participants are generally representative of the
typical DTC genetic testing user about which this study aims to draw
conclusions.36 Respondents to this study were broadly similar to the
sampling frame of 23andMe consumers invited to participate, although
our respondents were significantly more likely to be female. The con-
cern about representation and selection bias is enhanced for the Pathway
sample, however, since they were offered subsidized testing to partici-
pate. Second, survey research always faces the potential for response bias,
with some study participants choosing not to respond to certain surveys.
More than 70% of those surveyed at baseline responded to the survey at
6 months, and other evidence from the study population suggests that
nonresponse bias is unlikely to be a major problem.36
Third, comparability of our items across other studies faces survey
question wording issues. Our questions were not directly comparable
to other studies that chose to word items about access to or regula-
tion of PGT differently (such as variation in descriptions about the
310 S.E. Gollust et al.
role of medical professionals across studies). Fourth, our measures of
subjective response to testing may be vulnerable to recall bias since
participants were asked at 6 months after testing to recall both their
results and their emotional reaction to testing. Fifth, respondents may
have interpreted the wording of the survey items with variation. In par-
ticular (and discussed in greater depth below), this study was mainly
concerned with expanding or restricting access to PGT. However, ac-
cess is only one component of federal policy attention and oversight.
In fact, a great deal of regulatory attention to these services has
concerned ascertaining the clinical importance, impact, and techni-
cal accuracy of test results. Research by Bollinger and colleagues,29
who did include more diverse measures of attitudes about regulation,
suggests that consumers may have more supportive views toward a
governmental role in regulation of test quality compared to restricting
access completely. Our study did not ask consumers’ views about the
value of these distinct regulatory objectives; consumers may have inter-
preted our single item about government regulation in different ways,
which could explain why political ideology was most strongly associated
with attitudes about regulation. Respondents likely used their attitudes
about government as a shortcut to answering this question, rather than
relying on a more informed understanding of genetic test regulation.
Conclusions and Policy Implications
Our results describe a population of PGT consumers that want to see
expanded access to PGT services and who voiced moderate to strong op-
position to federal regulation. An important question, however, concerns
the extent to which these attitudes matter in the dynamic policymaking
process over PGT. On the one hand, legislative priorities in a demo-
cratic political system are ideally meant to be accountable to public
demands.49 On the other hand, after legislation has passed, public in-
terest in a medical product typically does not play a major or formal role
in agency regulatory decisions, such as that of the FDA. Historical ex-
ceptions exist, of course, such as the experience of HIV activists shaping
FDA decisions around access to drugs.50 More recently, state legislative
branches have compelled or restricted use of drugs against FDA approval
or intent (eg, requiring drug access for emergency uses, mandating on-
label use of drugs that can cause abortions).51,52 Regulatory agencies like
the FDA are increasingly moving toward more patient and consumer
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involvement, such as including consumers on advisory committees and
more involved deliberative processes to engage patients.53 For instance,
the FDA convenes advisory committee meetings debating whether to
recommend approval for a new drug application (however, their influ-
ence on the actual approval process is limited).54 Public interest can
encourage the FDA to assign a product a higher “enforcement priority”
and use its regulatory authority to compel quality compliance (as it did
for DTC genetic testing in 2010 and 2013).15 The fact that the PGT
users in this study would like to see expanded access could shape, at
least in a limited way, regulatory actions moving forward, since greater
consumer interest and utilization often leads to greater regulatory in-
volvement. The fact that the majority of those surveyed did not believe
that the government should put more effort into regulation reveals an
interesting disconnect between consumer attitudes and the FDA’s regu-
latory structure: Public interest can increase FDA enforcement priority
in ensuring that a manufacturer has established the safety and efficacy of
a device (as, indeed, the FDA confirmed for several genetic risk reports
in April 2017). If it has not, the FDA’s recourse is to restrict access.
Finally, while our survey focused mainly on access to services, it
is important to reiterate that the bulk of governmental inquiry into
the DTC genetic-testing industry has focused on quality: the accuracy,
reliability, and clinical utility of the information returned. After all, if the
DTC genetic information is unreliable and inaccurate, access is worthless
or harmful. Perhaps this quality concern is what drove the 27.8% of
participants who stated an interest in more government regulation, but
as noted above in limitations, we did not ask about specific regulatory
objectives of the government. These data highlight the tension between
consumer knowledge of and interest in a product and the mechanics of
the regulatory approval process. They also underscore the need for future
research to supplement these quantitative (and largely decontextualized)
survey data with qualitative interviews and deliberative approaches55
that both educate and engage participants in the ongoing policy debate.
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Appendix: Consumers’ Attitudes About Regulation and
the Ethics of Direct Access to Genetic Testing (N= 941)
Overall
Agree
a
Strongly
Disagree
Some-
what
Disagree
Neither
Agree
nor
Disagree
Some-
what
Agree
Strongly
Agree
I think people have
a right to access
their own
genetic
information
without going
through a
medical
professional.
845
(89.9%)
13
(1.4%)
15
(1.6%)
67
(7.1%)
219
(23.3%)
626
(66.6%)
It is important to
me that my
genetic
information is
kept private.
783
(83.2%)
31
(3.3%)
34
(3.6%)
93
(9.9%)
215
(22.8%)
568
(60.4%)
I think that parents
should be able to
get results for
their children if
they want to.
767
(81.5%)
13
(1.4%)
27
(2.9%)
134
(14.2%)
290
(30.8%)
477
(50.7%)
Genetic tests
should be
available more
widely (eg, test
kits at drug
stores).
643
(68.3%)
45
(4.8%)
80
(8.5%)
173
(18.4%)
298
(31.7%)
345
(36.7%)
Continued
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Appendix. Continued
Overall
Agree
a
Strongly
Disagree
Some-
what
Disagree
Neither
Agree
nor
Disagree
Some-
what
Agree
Strongly
Agree
I think genetic
information
should be part of
a standard
medical record.
592
(62.9%)
76
(8.1%)
91
(9.7%)
182
(19.3%)
280
(29.8%)
312
(33.2%)
I think that health
insurance should
cover personal
genomic testing.
567
(60.3%)
70
(7.4%)
84
(8.9%)
220
(23.4%)
259
(27.5%)
308
(32.7%)
I think the
government
should put more
effort into
regulating
personal
genomic testing.
261
(27.8%)
242
(25.7%)
131
(13.9%)
306
(32.6%)
157
(16.7%)
104
(11.1%)
Tests like these
should only be
available to
people through
their doctor.
135
(14.3%)
484
(51.4%)
191
(20.3%)
131
(13.9%)
62
(6.6%)
73
(7.8%)
aOverall agree is the sum of somewhat agree and strongly agree.
